Symbion set to lift EBOS
August 22, 2013
THE acquisition of Symbion
Healthcare by NZ-based EBOS
(PD 29 May) has been a “game
changer” for the Christchurch
company, which yesterday reported
its results to 30 Jun.
EBOS md Mark Waller said
the deal meant the group now
has “strong market positions
with excellent systems and
management in all our businesses
in Australia and New Zealand, with
opportunities for further growth”.
Although it’s still early days, with
just over two weeks of Symbion
trading included in the full year
figures, Waller said “work is
progressing on leveraging the
strengths of EBOS and Symbion,”
with an immediate focus on
translating EBOS’s experience in
third party logistics to Symbion.
Total revenue for the year was
NZ$1.823 billion, up 27.6%,
while net profit after tax was
NZ$28.2 million including a $4.7m
contribution attributable to the
Symbion Group.
If Symbion had been part of the
EBOS for the full year the total
revenue would have been $6.24
billion, and the group profit would
have been $90m, indicating that
Symbion’s full year profit was
around NZ$66 million (A$57.7m).
EBOS chairman Rick Christie also
confirmed that work is under way
to facilitate the dual listing of the
group’s shares on the ASX (PD 30
May) which will give increased
investor awareness of the firm.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Aug 13To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Aug 13
